Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Budesonide and Albuterol MDI HFO vs HFA in Healthy Participants
NCT06139991Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of budesonide and salbutamol in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time 0 to the last quantifiable concentration at Day 2 and Maximum plasma drug concentration at Day 2. Started Nov 2023; status: completed.
02
Drugs
budesonidesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06139991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139991.